title: New drugs for bipolar disorder.
abstract: Bipolar disorder (BD) is one of the most potentially severe mental disorders. Literature data indicate that despite the current available treatments, a large proportion of patients do not achieve complete remission, with consequent residual symptoms and chronic impairment. We carried out a comprehensive review of new pharmacologic treatments for BD. Even though the core treatment of BD likely will not likely undergo substantial changes over the next few years, many promising results with respect to new augmentation strategies were identified. New treatments for bipolar depression and for BD-related cognitive impairment seem to represent particularly fertile areas of research.
authors.affiliation: University of Texas Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, 1541 East Road, Houston, TX 77054, USA. marsal.sanches@uth.tmc.edu
authors.forename: Marsal
authors.initials: M
authors.lastname: Sanches
authors.forename: Jair C
authors.initials: JC
authors.lastname: Soares
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D003072:Cognition Disorders / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D018691:Excitatory Amino Acid Antagonists; D006993:Hypnotics and Sedatives